XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
November 04, 2021 07:40 ET | XOMA Corporation
EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3...
XOMA-Logo-Final.png
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events
November 04, 2021 07:30 ET | XOMA Corporation
Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the treatment of...
XOMA-Logo-Final.png
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 22, 2021 07:30 ET | XOMA Corporation
EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare...
XOMA-Logo-Final.png
XOMA Declares Quarterly Preferred Stock Dividends
September 20, 2021 07:30 ET | XOMA Corporation
EMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA-Logo-Final.png
XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 13, 2021 07:30 ET | XOMA Corporation
EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global...
XOMA-Logo-Final.png
XOMA Announces Heather L. Franklin Joins its Board of Directors
August 10, 2021 16:35 ET | XOMA Corporation
EMERYVILLE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined...
XOMA-Logo-Final.png
XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events
August 05, 2021 07:30 ET | XOMA Corporation
Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Janssen asset entered Phase 3 development NIS793 in combination with...
XOMA-Logo-Final.png
U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA’s Licensed anti-TGFβ Asset NIS793
July 28, 2021 07:30 ET | XOMA Corporation
EMERYVILLE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug...
XOMA-Logo-Final.png
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences
July 15, 2021 04:00 ET | XOMA Corporation
EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate...
XOMA-Logo-Final.png
XOMA Declares Quarterly Preferred Stock Dividends
June 21, 2021 07:30 ET | XOMA Corporation
EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...